The Experts below are selected from a list of 47493 Experts worldwide ranked by ideXlab platform
Dennis Massie - One of the best experts on this subject based on the ideXlab platform.
-
from traditional inter library loan to a new interlending model the role of the curl monograph interlending pilot
Interlending & Document Supply, 2002Co-Authors: Stephen Prowse, Dennis MassieAbstract:The traditional inter‐library loan of Monographs is often seen as the future niche of interlending activity, with journal article supply being catered for by other means, such as full text access through e‐journals. Examines how a monograph interlending pilot project, undertaken by CURL institutions, is part of a move towards a more distributed interlending model for the UK. Describes the project, presents statistical figures, and outlines results from feedback questionnaires. Shows the relationship to SHARES, RLG’s interlending program, and how the pilot has affected international interlending. Calls for other models to support the new interlending paradigm.
-
from traditional inter library loan to a new interlending model the role of the curl monograph interlending pilot
Interlending & Document Supply, 2002Co-Authors: Stephen Prowse, Dennis MassieAbstract:The traditional inter‐library loan of Monographs is often seen as the future niche of interlending activity, with journal article supply being catered for by other means, such as full text access through e‐journals. Examines how a monograph interlending pilot project, undertaken by CURL institutions, is part of a move towards a more distributed interlending model for the UK. Describes the project, presents statistical figures, and outlines results from feedback questionnaires. Shows the relationship to SHARES, RLG’s interlending program, and how the pilot has affected international interlending. Calls for other models to support the new interlending paradigm.
Kurt Straif - One of the best experts on this subject based on the ideXlab platform.
-
towards incorporating epigenetic mechanisms into carcinogen identification and evaluation
Carcinogenesis, 2013Co-Authors: Zdenko Herceg, Kurt Straif, Mariepierre Lambert, Karin Van Veldhoven, Christiana A Demetriou, Paolo Vineis, Martyn T Smith, Christopher P WildAbstract:Remarkable progress in the field of epigenetics has turned academic, medical and public attention to the potential applications of these new advances in medicine and various fields of biomedical research. The result is a broader appreciation of epigenetic phenomena in the a etiology of common human diseases, most notably cancer. These advances also represent an exciting opportunity to incorporate epigenetics and epigenomics into carcinogen identification and safety assessment. Current epigenetic studies, including major international sequencing projects, are expected to generate information for establishing the ‘normal’ epigenome of tissues and cell types as well as the physiological variability of the epigenome against which carcinogen exposure can be assessed. Recently, epigenetic events have emerged as key mechanisms in cancer development, and while our search of the Monograph Volume 100 revealed that epigenetics have played a modest role in evaluating human carcinogens by the International Agency for Research on Cancer (IARC) Monographs so far, epigenetic data might play a pivotal role in the future. Here, we review (i) the current status of incorporation of epigenetics in carcinogen evaluation in the IARC Monographs Programme, (ii) potential modes of action for epigenetic carcinogens, (iii) current in vivo and in vitro technologies to detect epigenetic carcinogens, (iv) genomic regions and epigenetic modifications and their biological consequences and (v) critical technological and biological issues in assessment of epigenetic carcinogens. We also discuss the issues related to opportunities and challenges in the application of epigenetic testing in carcinogen identification and evaluation. Although the application of epigenetic assays in carcinogen evaluation is still in its infancy, important data are being generated and valuable scientific resources are being established that should catalyse future applications of epigenetic testing.
-
carcinogenicity of radiofrequency electromagnetic fields
Lancet Oncology, 2011Co-Authors: Robert A. Baan, Yann Grosse, Fatiha El Ghissassi, Beatrice Laubysecretan, Veronique Bouvard, Lamia Benbrahimtallaa, Neela Guha, Farhad Islami, Laurent Galichet, Kurt StraifAbstract:Robert Baan a, Yann Grosse a, Beatrice Lauby-Secretan a, Fatiha El Ghissassi a, Veronique Bouvard a, Lamia Benbrahim-Tallaa a, Neela Guha a, Farhad Islami a, Laurent Galichet a, Kurt Straif a, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group In May, 2011, 30 scientists from 14 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF). These assessments will be published as Volume 102 of the IARC Monographs.1
-
Meeting report: summary of IARC Monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol.
Environmental Health Perspectives, 2005Co-Authors: Vincent Cogliano, Marie Béatrice Secretan, Robert A. Baan, Yann Grosse, Kurt Straif, Fatiha El GhissassiAbstract:An international, interdisciplinary working group of expert scientists met in June 2004 to develop IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (IARC Monographs) on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol. Each IARC Monograph includes a critical review of the pertinent scientific literature and an evaluation of an agent’s potential to cause cancer in humans. After a thorough discussion of the epidemiologic, experimental, and other relevant data, the working group concluded that formaldehyde is carcinogenic to humans, based on sufficient evidence in humans and in experimental animals. In the epidemiologic studies, there was sufficient evidence that formaldehyde causes nasopharyngeal cancer, “strong but not sufficient” evidence of leukemia, and limited evidence of sinonasal cancer. The working group also concluded that 2-butoxyethanol and 1-tert-butoxy-2-propanol are not classifiable as to their carcinogenicity to humans, each having limited evidence in experimental animals and inadequate evidence in humans. These three evaluations and the supporting data will be-published as Volume 88 of the IARC Monographs.
Mei Wang - One of the best experts on this subject based on the ideXlab platform.
-
the role of the european pharmacopoeia ph eur in quality control of traditional chinese herbal medicine in european member states
Traditional Chinese Medicine, 2015Co-Authors: Mei Wang, Gerhard FranzAbstract:In order to assure the safety and efficacy of the Chinese Medicines in Europe, the quality of TCM herbals should be guaranteed so that they can be freely imported in the European Union and other Western European Countries which are signatories of the European Pharmacopoeia Convention. Consequently, new Ph Eur TCM herbal drug Monographs should be elaborated, based on preexisting Monographs in the Chinese Pharmacopoeia (ChP) 2010. Such a program has been inaugurated in 2005 by the Ph Eur Groups of Experts 13 A and B (Phytochemistry). Since then good progress has been made, elaborating of about one third of the originally proposed 100 TCM herbals being identified as important Monographs for the European Market. Taking into account the many challenges still laying ahead, the establishment of a specialized Working Party (WP) on TCM with specialists and experts from many EU Member States has been decided by the Ph Eur Commission in 2008 which is highly active ever since in the examination and elaboration of new TCM herbal drug Monographs, primarily to assure the safety of the European patient and further to provide quality parameters extremely important for all registration and licensing procedures of the respective National Authorities all over Europe. This paper is a survey of results and difficulties obtained so far which has been encountered meanwhile in the elaboration process by the Ph Eur TCM WP of these Monographs and will discuss these in detail. Moreover the role of Ph Eur TCM Monographs in the European community is addressed.
-
non european traditional herbal medicines in europe a community herbal monograph perspective
Journal of Ethnopharmacology, 2014Co-Authors: Wenjun Zou, Zhenxiang Zhou, Tingmo Zhang, Janvander Greef, Mei WangAbstract:Abstract Ethnopharmacological relevance The European Directive 2004/24/EC introducing a simplified registration procedure for traditional herbal medicinal products, plays an important role in harmonising the current legislation framework for all herbal medicinal products in the European Union (EU). Although substantial achievements have been made under the new scheme, only a limited number of herbal medicinal products from non-European traditions commonly used in Europe have been registered. Therefore, identification of the obstacles, and determination of appropriate means to overcome the major challenges in the registration of non-European traditional herbal medicinal products are of critical importance for the EU herbal medicinal product market. Aims of the study The primary aims of this study were to understand the key issues and obstacles to registration of non-European traditional herbal medicinal products within the EU. The findings may identify the need for more attention on the Community herbal Monographs elaborated by the Herbal Medicinal Products Committee (HMPC), as well as further evidence based scientific research on non-European herbal substances/preparations by the scientific community. Methods A systematic evaluation of the herbal substances and preparations included in Community herbal Monographs and public statements has been carried out. The focus was herbal substances and preparations derived from non-European traditions. Results Of the 109 adopted Community herbal Monographs, 10 are herbal substances used in Chinese traditional medicine. Where the HMPC issued a public statement because it was unable to elaborate a monograph more than half-involved herbal substances/preparations from non-European traditions. The main reasons herbal substances/preparations from non-European traditions were not accepted for inclusion in the Community herbal Monographs have been identified as due to unfulfilled requirements of Directive 2004/24/EC. The most common reasons were the lack of evidence to demonstrate a 15-year minimum medicinal use period in the EU and evidence of absence of health risk as required by Article 16a (1) (d), and Article 16a (1) (e). Conclusions Under the current EU legislation, the requirement to demonstrate 15-year minimum medicinal use in the EU is a major obstacle to the registration of non-European traditional herbal medicinal products. Access to scientific data to support the product safety profile may be a possible solution to overcome the hurdle presented by the 15-year minimum medicinal use period. Furthermore, the Community herbal Monographs play an important role in the registration process. Therefore, making full use of existing Community herbal Monographs, and promoting scientific research and subsequent development of additional Monographs for herbal substances and preparations, and combinations thereof from non-European traditions would be of benefit to herbal medicinal product registration from non-European traditions.
Peishan Xie - One of the best experts on this subject based on the ideXlab platform.
-
high performance thin layer chromatographic fingerprints of isoflavonoids for distinguishing between radix puerariae lobate and radix puerariae thomsonii
Journal of Chromatography A, 2006Co-Authors: Sibao Chen, Albert S. C. Chan, Heping Liu, Runtao Tian, Dajian Yang, Shilin Chen, Peishan XieAbstract:The roots of Pueraria lobata (Wild.) Ohwi and Pueraria thomsonii Benth have been officially recorded in all editions of Chinese Pharmacopoeia under the same monograph 'Gegen' (Radix Puerariae, RP). However, in its 2005 edition, the two species were separated into both individual Monographs, namely 'Gegen' (Radix Puerariae Lobatae, RPL) and 'Fenge' (Radix Puerariae Thomsonii, RPT), respectively, due to their obvious content discrepancy of puerarin, the major active constituent. In present paper, the fingerprint of high-performance thin-layer chromatography (HPTLC) combining digital scanning profiling was developed to identify and distinguish the both species in detail. The unique properties of the HPTLC fingerprints were validated by analyzing ten batches of Pueraria lobata and P. thomsonii samples, respectively. The common pattern of the HPTLC images of the roots of Pueraria spp. and the respective different ratios of the chemical distribution can directly discern the two species. The corresponding digital scanning profiles provided an easy way for quantifiable comparison among the samples. Obvious difference in ingredient content and HPTLC patterns of the two species questioned their bio-equivalence and explained that recording both species separately in the current edition of Chinese Pharmacopoeia (2005 edition) is reasonable due to not only the content of major constituent, puerarin, but also the peak-to-peak distribution in the fingerprint and integration value of the total components. Furthermore, the HPTLC fingerprint is also suitable for rapid and simple authentication and comparison of the subtle difference among samples with identical plant resource but different geographic locations.
Fatiha El Ghissassi - One of the best experts on this subject based on the ideXlab platform.
-
carcinogenicity of radiofrequency electromagnetic fields
Lancet Oncology, 2011Co-Authors: Robert A. Baan, Yann Grosse, Fatiha El Ghissassi, Beatrice Laubysecretan, Veronique Bouvard, Lamia Benbrahimtallaa, Neela Guha, Farhad Islami, Laurent Galichet, Kurt StraifAbstract:Robert Baan a, Yann Grosse a, Beatrice Lauby-Secretan a, Fatiha El Ghissassi a, Veronique Bouvard a, Lamia Benbrahim-Tallaa a, Neela Guha a, Farhad Islami a, Laurent Galichet a, Kurt Straif a, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group In May, 2011, 30 scientists from 14 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF). These assessments will be published as Volume 102 of the IARC Monographs.1
-
Meeting report: summary of IARC Monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol.
Environmental Health Perspectives, 2005Co-Authors: Vincent Cogliano, Marie Béatrice Secretan, Robert A. Baan, Yann Grosse, Kurt Straif, Fatiha El GhissassiAbstract:An international, interdisciplinary working group of expert scientists met in June 2004 to develop IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (IARC Monographs) on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol. Each IARC Monograph includes a critical review of the pertinent scientific literature and an evaluation of an agent’s potential to cause cancer in humans. After a thorough discussion of the epidemiologic, experimental, and other relevant data, the working group concluded that formaldehyde is carcinogenic to humans, based on sufficient evidence in humans and in experimental animals. In the epidemiologic studies, there was sufficient evidence that formaldehyde causes nasopharyngeal cancer, “strong but not sufficient” evidence of leukemia, and limited evidence of sinonasal cancer. The working group also concluded that 2-butoxyethanol and 1-tert-butoxy-2-propanol are not classifiable as to their carcinogenicity to humans, each having limited evidence in experimental animals and inadequate evidence in humans. These three evaluations and the supporting data will be-published as Volume 88 of the IARC Monographs.
